newsfilter
← Latest News
GlobeNewswire·

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal